1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. GRACE THERAPEUTICS INC.
Grace Therapeutics Inc.
XNAS: GRCE
Download real time
2.080.04(1.96%)
59.85% Fall from 52W High
37,792
XNAS Volume

XNAS 09 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Grace Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Grace Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • NEUTRAL

    Quarterly Revenue Grace Therapeutics Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Quarterly Net Profit Grace Therapeutics Inc Jun-2026 Quarterly Net Profit is $-16 Million which is growth of -369.7% YoY.

Grace Therapeutics Inc., Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
2.432.52.53.13.23.74.853.332.13
Operating Profit
-2.4-3-2.5-2.5-3.1-3.2-3.7-4.8-5-3.3-3-2.1-3
⌄
0.10.10.20.20.20.20.10.20.20.30.30.20.1
Profit Before Tax
-15.8-2.9-2.3-0.9-3.4-0.4-4.8-4.3-3.3-4.1-2.6-3.7-4.3
Tax
-1.7-1-0.6-0.9-0.7-0.9-0.2-0.5-0.3
⌄
-15.8-1.2-2.3-0.9-3.40.6-4.2-3.4-2.6-3.2-2.4-3.3-4
Diluted NI Avail to Com Stockholders Ann.
-15.8-1.2-2.3-0.9-3.40.6-4.2-3.4-2.6-3.2-2.4-3.3-4
Basic EPS
-0.9-0.1-0.1-0.1-0.20.1-0.4-0.3-0.2-0.3-0.2-0.4-0.5
Diluted EPS After ExtraOrdinary
-0.1-0.1-0.1-0.2-0.2-0-0.3-0.3-0.3-0.2-0.2-0.2-0.4
Number Of Shares End
17.317.316.915.915.913.811.511.510.911.511.57.67.4
Net Income Continuing Discontinued Operations
-15.8-1.2-2.3-0.9-3.40.6-4.2-3.4-2.6-3.2-2.4-3.3-4
Normalized Income
-2.2-1-2.2-2.2-2.6-1.4-3-3.6-3.5-2.2-2.2-1.4-2.6
Interest Income
0.10.10.20.20.20.20.10.20.20.30.30.20.1
Interest
-------------
Net Interest Income
0.10.10.20.20.20.20.10.20.20.30.30.20.1
EBIT
-15.9-3-2.5-1.1-3.6-0.6-4.9-4.5-3.6-4.3-2.9-3.9-4.5
EBITDA
-15.9-3-2.5-1.1-3.6-0.6-4.9-4.5-3.6-4.3-2.9-3.9-4.4
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
0
Profit From Continuing Operations
-15.8-1.2-2.3-0.9-3.40.6-4.2-3.4-2.6-3.2-2.4-3.3-4
Normalized EBITDA
11.2-3-2.4-4-2.6-5.8-2.5-5.2-6.4-2.2-3.2-0.3-1.5
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Grace Therapeutics Inc competitor comparison and performance snapshot within industry

Grace Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEUTRAL

    Annual Revenue Grace Therapeutics Inc Annual Revenue is $0 Million which is growth of 0% YoY.

  • POSITIVE

    Annual Net Profit Grace Therapeutics Inc Annual Net Profit is $-8 Million which is growth of 18.6% YoY.

Grace Therapeutics Inc., Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Feb '16Feb '15
⌄
-
-
 0.200.2
Cost Of Rev. Ann.
-
-
 ----0.1---0.10.2
Gross Profit Ann.
-
-
 ----0.1----00
Operating Exp. Ann.
-15.4%
0.5%
10.411.116.711.418.315.310.824.43315.37.19.9
Operating Profit Ann.
-
-
-10.4-11.1-16.7-11.4-18.3-15.3-10.7-24.4-33-15.3-7.1-9.9
⌄
32.6%
-
0.60.70.70.90.30.2-0.20-0.4-1.10.10.1
Other Exp. Ann.
-
-
 0.93.2-4.2-344.7-8.8-1.1-5.2-0.32.48.5
PBT Ann.
-
-
-21.9-9.5-12.8-14.7-52-10.5-19.7-25.5-38.6-16.7-4.7-1.3
Tax Ann.
-
-
-1.7-1.7-3.2-1.8-9.5-0.7-----
⌄
-
-
-20.2-7.8-9.6-12.9-42.4-9.8-19.7-25.5-38.6-16.7-4.7-1.3
Diluted NI Avail to Com Stockholders Ann.
-
-
-20.2-7.8-9.6-12.9-42.4-9.8-19.7-25.5-38.6-16.7-4.7-1.3
EPS Ann.
-
-
 -0.5-0.8-1.4-5.7-1.6-8.2-14.4-34.7-46-21.7-8.5
Diluted EPS Ann.
-
-
 -0.5-0.8-1.4-5.7-1.6-8.2-14.4-34.7-46-21.7-8.5
Number Of Shares End
32.1%
32.1%
 17.313.811.57.57.44.31.91.60.50.20.2
Total Exp. Ann.
-15.4%
0.4%
 11.116.711.418.315.310.924.43315.37.110.1
Net Income Continuing Discontinued Operations Ann.
-
-
-20.2-7.8-9.6-12.9-42.4-9.8-19.7-25.5-38.6-16.7-4.7-1.3
Normalized Income Ann.
-
-
-7.5-7.9-11.4-8.4-12.4-13.6-9.6-22.2-32.5-15.8-6-7.9
Interest Income Ann.
32.6%
47.6%
0.60.70.70.90.30.10.10.30.40.10.10.1
Interest Ann.
-
-
 -----0.30.30.3
EBITDA Ann.
-
-
-22.5-10.2-13.5-15.6-52.1-10.5-18.9-23.3-37.2-14.4-3.10.5
Reconciled Cost Of Rev. Ann.
-
-
 ----0.1---0.10.2
Reconciled Depr. Ann.
-
-
00000.10.92.32.12.11.81.9
Profit From Continuing Operations Ann.
-
-
-20.2-7.8-9.6-12.9-42.4-9.8-19.7-25.5-38.6-16.7-4.7-1.3
Normalized EBITDA Ann.
-
-
1.8-12-19.9-7.115.9-20-10-21.8-31-14-5.3-8
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Operating Exp. Ann.
1Y CHG
-33.5%
2Y CAGR
-1.3%
3Y CAGR
-15.4%
5Y CAGR
0.5%
7Y CAGR
-14.4%
10Y CAGR
4.6%
Operating Expenses Annual Cr is falling faster than historical averages.

Grace Therapeutics Inc balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Total Shareholders Fund Grace Therapeutics Inc Mar-2026 Total Shareholders Fund is $64 Million which is growth of -4.1% YoY.

  • NEGATIVE

    Total Assets Grace Therapeutics Inc Mar-2026 Total Assets is $67 Million which is growth of -7.4% YoY.

Grace Therapeutics Inc., Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Feb '16Feb '15
⌄
-5.5%
1.3%
66.77273.379.1128.662.522.936.317.82129.7
⌄
-37%
-16.3%
2.85.411.611.220.46.89.925.911.413.2
⌄
-2.1%
2.8%
63.966.661.768108.355.71310.56.420.126.6
Total Capitalization Ann.
-2.1%
2.8%
63.966.661.768108.355.71310.57.620.126.6
Tangible Assets Ann.
-7.9%
-23.5%
14.617.312.518.725.555.78.84.7-1.49.112.6
Working Capital Ann.
-16.3%
-24.2%
15.220.822.325.942.360.88.714.32.27.514.4
Invested Capital Ann.
-2.1%
2.8%
63.966.661.768108.355.71311.87.620.126.6
Tangible Book Value Ann.
-7.9%
-23.5%
14.617.312.518.725.555.78.84.7-1.49.112.6
Borrowings Ann.
-
-
--0.50.30.10.21.41.3--
Net Debt Ann.
-
-
-----------
Share Issued Ann.
29.3%
30.1%
1613.79.47.47.44.31.91.60.50.20.2
Number Of Shares End
32.1%
32.1%
17.313.811.57.57.44.31.91.60.50.20.2
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
-7.4%
2Y CAGR
-4.6%
3Y CAGR
-5.5%
5Y CAGR
1.3%
7Y CAGR
9.1%
10Y CAGR
12.3%
Total Assets Annual is falling faster than historical averages.
Total Current Liabilities Ann.
1Y CHG
15.8%
2Y CAGR
13.8%
3Y CAGR
-13.5%
5Y CAGR
6.6%
7Y CAGR
-23%
10Y CAGR
10.6%
Total Current Liabilities Annual Cr growth is higher than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
-4.1%
2Y CAGR
1.8%
3Y CAGR
-2.1%
5Y CAGR
2.8%
7Y CAGR
29.4%
10Y CAGR
12.3%
Total ShareHolders Funds Annual is falling faster than historical averages.

Grace Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Book Value Per Share Grace Therapeutics Inc Book Value Per Share is $4 which is growth of -11.9% YoY.

  • POSITIVE

    ROE Grace Therapeutics Inc ROE is -12% which is growth of 3.0% YoY.

Grace Therapeutics Inc., Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Feb '16Feb '15
RoA Ann. %
-
-
-11.24%-13.17%-16.86%-40.85%-10.28%-46.13%-86.26%-142.83%-90.33%-18.36%-3.74%
ROE Ann. %
-
-
-11.94%-14.91%-19.82%-48.15%-11.98%-57.33%-217.59%-459.08%-147.08%-19.99%-4.68%
ROIC %
-
-
-20.9-5.3-35.3-3.5-13.9345.2-73.9-57.1-6.722.3
OPM Ann. %
-
-
------5,467.35%----25,522.56%-4,580.10%
Inventory Turnover Ratio Ann.
-
-
---------1.71.2
Asset Turnover Ann. %
-
-
--------0
Working Capital Turnover Ann.
-
-
0
Quick Ratio Ann.
-2%
-27.3%
7.911.514.18.413.638.8221.39.511.9
Current Ratio Ann.
-2%
-27.2%
8.111.814.38.61439.52.22.11.49.912.1
Interest Coverage Ratio Ann.
-
-
-------102.3-140.3-57.8-2,792.8-406.6
LT Debt To Equity Ann.
-
-
---0-0-0.2--
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Current Ratio Ann.
1Y CHG
-31.4%
2Y CAGR
-24.7%
3Y CAGR
-2%
5Y CAGR
-27.2%
7Y CAGR
21.3%
10Y CAGR
-2%
Current Ratio Annual is falling faster than historical averages.

Grace Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Cash From Operating Activity Grace Therapeutics Inc Cash From Operating Activity is $-9 Million which is growth of 40.5% YoY.

  • NEGATIVE

    Net Cash Flow Grace Therapeutics Inc Net Cash Flow is $-5 Million which is growth of -491.3% YoY.

Grace Therapeutics Inc., Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Feb '16Feb '15
⌄
-
-
-8.9-14.9-12.3-15.9-17.2-14.3-22.9-24.3-9.7-4.9-5.8
⌄
-
-
0.113.2-3.5-9.98.1-9.1-0.36.16.1
⌄
131%
-42.6%
3.7147.40.359.513.244.18.80
Cash Plus Cash Eqv. End Of Year Ann.
-15.2%
-19.7%
1722.12327.930.350.914.216.96.42.21.1
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
-5.2-0.9-4.9-2.5-20.835.3-1.610.7-1.21.20.4
Cash Plus Cash Eqv. Begin Of Year Ann.
-10%
9.2%
22.12327.930.350.914.216.96.27.610.5
Income Tax Paid Supplemental Data Ann.
-
-
-----------
Interest Paid Supplemental Data Ann.
-
-
-----------
Capex Ann.
-
-
---0-0--0.1-0.3-0.5-0.4-0.3-0.1
Issuance Of Capital Stock Ann.
-
16.5%
157.30.359.3743.48.6
Issuance Of Debt Ann.
-
-
-----------
Repayment Of Debt Ann.
-
-
------1.6----
Repurchase Of Capital Stock Ann.
-
-
---------0--
Free Cash Flow Ann.
-
-
-8.9-14.9-12.4-15.9-17.2-14.4-23.3-25.3-10.1-5.3-6.5
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
-73.6%
2Y CAGR
-29.3%
3Y CAGR
131%
5Y CAGR
-42.6%
7Y CAGR
-29.8%
Cash from Financing Annual Activity is falling faster than historical averages.
×